Drug information provided by: Merative, Micromedex®
Brentuximab injection is used to treat Hodgkin lymphoma, systemic anaplastic large cell lymphoma (sALCL), and primary cutaneous anaplastic large cell lymphoma (pcALCL), which are blood cancers. It is given to patients who have received a bone marrow (autologous stem cell) transplant or other cancer treatments that did not work well.
Brentuximab injection is also used together with other cancer medicines (eg, doxorubicin, vinblastine, vincristine, dacarbazine, etoposide, prednisone, and cyclophosphamide) to treat a previously untreated high risk or stage III or IV classical Hodgkin lymphoma.
Brentuximab injection is also used together with other medicines (eg, cyclophosphamide, doxorubicin, prednisone) to treat patients with previously untreated sALCL or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL.
Brentuximab interferes with the growth of cancer cells, which are then destroyed by the body.
This medicine is to be given only by or under the direct supervision of your doctor.
This product is available in the following dosage forms:
Portions of this document last updated: Sept. 01, 2023
لا تُقدم Mayo Clinic الدعم للشركات أو المنتجات المُعلَّن عنها هنا. لكن تدعم العائدات الإعلانية رسالتنا غير الربحية.
تحقق من هذه الكتب الأكثر مبيعًا والعروض الخاصة على الكتب والنشرات الإخبارية من Mayo Clinic Press.
تساهم التبرّعات، وهي قابلة للخصم الضريبي، في دعم آخر التطورات في الأبحاث وطرق الرعاية لإحداث نقلة نوعية في الطب.